Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of weekly subcutaneous ALXN1720 in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis
NL-OMON56009Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing ALXN1720 with Placebo (2 arms). Primary endpoint: Change from baseline in Myasthenia Gravis Activities of Daily Living total score at Week 26. Started Sep 2024; status: recruiting.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON56009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56009.